title: Treatment of 5q-syndrome with lenalidomide in an HIV-positive patient under cART.
authors.forename: Sabine
authors.initials: S
authors.lastname: Blum
authors.forename: Matthias
authors.initials: M
authors.lastname: Cavassini
authors.forename: Jean-François
authors.initials: JF
authors.lastname: Lambert
authors.forename: Aurélie
authors.initials: A
authors.lastname: Fayet
authors.forename: Marc
authors.initials: M
authors.lastname: Schapira
authors.forename: Martine
authors.initials: M
authors.lastname: Jotterand
mesh_terms: D019380:Anti-HIV Agents / Q000627:therapeutic use*; D002872:Chromosome Deletion; D002895:Chromosomes, Human, Pair 5; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D006801:Humans; D000077269:Lenalidomide; D018655:Lymphocyte Count; D008214:Lymphocytes / Q000187:drug effects / Q000276:immunology / Q000473:pathology; D008297:Male; D008875:Middle Aged; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D019380:Anti-HIV Agents; D013792:Thalidomide; D000077269:Lenalidomide